IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Farina, Mirko
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.679
AS - Asia 3.536
EU - Europa 2.447
SA - Sud America 600
Continente sconosciuto - Info sul continente non disponibili 168
AF - Africa 99
OC - Oceania 17
Totale 11.546
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.484
SG - Singapore 1.444
IT - Italia 1.008
CN - Cina 784
BR - Brasile 490
HK - Hong Kong 333
DE - Germania 309
BD - Bangladesh 299
VN - Vietnam 247
FR - Francia 198
FI - Finlandia 187
GB - Regno Unito 134
UA - Ucraina 121
RU - Federazione Russa 109
CA - Canada 106
TR - Turchia 101
IN - India 93
IE - Irlanda 51
PL - Polonia 51
NL - Olanda 49
MX - Messico 44
SE - Svezia 43
ZA - Sudafrica 43
CZ - Repubblica Ceca 41
JP - Giappone 39
IQ - Iraq 38
AR - Argentina 36
ES - Italia 32
AT - Austria 31
ID - Indonesia 19
BE - Belgio 18
EC - Ecuador 18
AU - Australia 16
CO - Colombia 15
SA - Arabia Saudita 15
EG - Egitto 14
UZ - Uzbekistan 12
CR - Costa Rica 11
MA - Marocco 11
VE - Venezuela 11
TH - Thailandia 10
KR - Corea 9
PY - Paraguay 9
JM - Giamaica 8
JO - Giordania 8
LT - Lituania 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
GR - Grecia 7
IL - Israele 7
KG - Kirghizistan 7
MY - Malesia 7
OM - Oman 7
DZ - Algeria 6
NP - Nepal 6
PA - Panama 6
PS - Palestinian Territory 6
PT - Portogallo 6
CH - Svizzera 5
CL - Cile 5
ET - Etiopia 5
IR - Iran 5
KE - Kenya 5
KZ - Kazakistan 5
PH - Filippine 5
RO - Romania 5
SN - Senegal 5
TW - Taiwan 5
UY - Uruguay 5
AL - Albania 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
LB - Libano 4
LK - Sri Lanka 4
LV - Lettonia 4
MD - Moldavia 4
TN - Tunisia 4
AZ - Azerbaigian 3
BO - Bolivia 3
EE - Estonia 3
GT - Guatemala 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
BG - Bulgaria 2
BS - Bahamas 2
CI - Costa d'Avorio 2
HU - Ungheria 2
NO - Norvegia 2
SV - El Salvador 2
AM - Armenia 1
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CG - Congo 1
CY - Cipro 1
GH - Ghana 1
HN - Honduras 1
HR - Croazia 1
IM - Isola di Man 1
Totale 11.365
Salva come PNG Salva come JPEG
Città #
Singapore 808
Ashburn 517
San Jose 452
Hong Kong 330
New York 243
Beijing 182
Fairfield 180
Dallas 174
The Dalles 174
Munich 161
Los Angeles 157
Brescia 134
Council Bluffs 126
Chandler 118
Helsinki 117
Lauterbourg 97
Milan 97
Columbus 95
Woodbridge 91
Seattle 87
Wilmington 80
Houston 79
Jacksonville 79
Ho Chi Minh City 78
Santa Clara 76
Des Moines 74
Princeton 68
Istanbul 67
Rome 63
Hanoi 58
São Paulo 57
Buffalo 54
Shanghai 54
Chicago 51
Boardman 50
Turku 50
Cambridge 47
Dublin 46
San Francisco 46
Redondo Beach 44
Moscow 40
Warsaw 37
Orem 36
Frankfurt am Main 35
Tokyo 34
Toronto 33
Ann Arbor 32
London 32
Denver 28
Brno 26
Brooklyn 26
Montreal 26
Johannesburg 25
Nuremberg 23
Phoenix 23
Atlanta 22
Turin 22
Mexico City 21
Stockholm 20
Romola 19
Chennai 18
Boston 17
Paris 17
Poplar 17
Lappeenranta 16
Pune 16
Charlotte 15
Manchester 15
San Diego 15
Tianjin 14
Verona 14
Da Nang 13
Florence 13
Nanchang 13
Nanjing 13
Wroclaw 13
Baghdad 12
Barlassina 12
Mumbai 12
Vienna 12
Amsterdam 11
Bologna 11
Brussels 11
Rio de Janeiro 11
Tashkent 11
Belo Horizonte 10
Biên Hòa 10
Brasília 10
Newark 10
Philadelphia 10
Bergamo 9
Dearborn 9
Düsseldorf 9
Genoa 9
Jinan 9
Olomouc 9
Amman 8
Buenos Aires 8
Cairo 8
Calgary 8
Totale 6.599
Salva come PNG Salva come JPEG
Nome #
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors and Circulating Endothelial Cells in Patients With Primary Myelofibrosis 249
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 211
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome 192
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 187
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 182
Advances in CMV Management: A Single Center Real-Life Experience 177
Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma 176
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 167
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 166
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 162
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 161
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent 156
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 155
Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia 153
Is the New Tci Score Sufficient to Categorize the Intensity of Conditioning? a Single-Centre Study 150
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 150
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 148
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 147
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 147
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 140
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 135
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 134
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA 132
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 131
Nutritional intervention with TGF-beta enriched food for special medical purposes (TGF-FSMP) is associated with a reduction of malnutrition, acute GVHD, pneumonia and may improve overall survival in patients undergoing allogeneic hematopoietic stem transplantation 130
Pre-Emptive Donor Lymphocyte Infusion As Optimal Treatment for Relapsed Acute Myeloid Leukemias and Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation: Insights from a French-Italian Study on 134 Patients 130
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 130
Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients 129
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 129
3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients 128
Identification of Relapse Risk Using a Multiparameter Flow Cytometry-Based Detection of Minimal Residual Disease in Adult Patients with Acute Myeloid Leukemia at ELN Intermediate-Risk 127
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 126
OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 124
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey) 124
Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection 123
Comparative monitoring of deep molecular response (DMR) by RT-quantitative (RT-qPCR) and digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) patients treated with TKIs for recognition of stable deep molecular response (DMR) and identification of best candidates to TKIs treatment discontinuation. 121
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol) 114
Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients 113
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis 113
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients 111
Nutritional strategies to improve VRE control 111
Potentiality of Bone Marrow-Derived Mesenchymal Stromal Cells (BM-MSCs) to Differentiate into the Osteogenic Lineage in in Vitro Model of Tissue Regeneration 110
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors 108
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2) 107
Evaluation of Circulating Endothelial Cells (CECs) As Marker of Endothelial Damage in Allo-Transplanted Patients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): The Cecinvod Study 107
Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study 106
Neuro-toxoplasmosis in haploidentical haematopoietic stem cell transplant 104
Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report 103
Immune Reconstitution after Allogenic Stem Cell Transplantation in Patients with Myelofibrosis 103
Impact of transforming growth factor-β2 enriched food for special medical purposes on nutritional status, microbiota and clinical outcomes after allogeneic hematopoietic stem cell transplantation: prospective analysis of 192 consecutive patients 102
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis 102
Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS‐Relapse Registry Study 102
dsDNA from extracellular vesicles (EVs) in adult AML 102
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation 100
PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY 100
PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY 98
Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French–Italian Experience of 134 Patients 96
POST REMISSION SEQUENTIAL MONITORING OF MINIMAL RESIDUAL DISEASE BY WT1 Q-PCR AND MULTIPARAMETRIC FLOW CYTOMETRY PREDICTS RELAPSE AND MAY HELP TO ADDRESS THE RISK ADAPTED THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS 96
How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation 96
PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS 95
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan 92
In Vitro Biocompatibility Assessment of Bioengineered PLA-Hydrogel Core–Shell Scaffolds with Mesenchymal Stromal Cells for Bone Regeneration 90
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 88
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 88
Assessment of Chronic Myeloid Leukaemia In Vitro Models Variability: Insights Into Extracellular Vesicles 85
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms 85
Exosomes and Extracellular Vesicles in Myeloid Neoplasia: The Multiple and Complex Roles Played by These “Magic Bullets” 84
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia 84
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study 84
Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey) 83
Real-world outcomes of total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation: A single-center retrospective study 83
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study 83
Intensive Chemotherapy Versus Venetoclax-Based Regimens in Elderly Patients with Acute Myeloid Leukemia: Is the Chemotherapy Era Ending? 81
S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 80
Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation (Bone Marrow Transplantation, (2023), 10.1038/s41409-023-02124-y) 79
Isolated Cerebral Myeloid Sarcoma in an Allogeneic Stem Cell Transplant Recipient 77
Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients 75
MALNUTRITION AND GVHD IN ALLOGENIC BONE MARROW TRANSPLANTATION: A PROSPECTIVE STUDY 75
CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB 75
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study 74
Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors 70
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study 67
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 66
Successful CAR-T cell therapy in a refractory mcl patient with rapidly progressive disease: a case report 65
Digital PCR as a New Method for Minimal Residual Disease Monitoring and Treatment Free Remission Management in Chronic Myeloid Leukemia Patients: Is It Reliable? 65
S157: BCR::ABL1 DIGITAL PCR IDENTIFIES CHRONIC PHASE CML PATIENTS SUITABLE FOR AN EARLY TKI DISCONTINUATION ATTEMPT: A PATIENT-LEVEL META-ANALYSIS 63
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 63
A case of Severe Gastrointestinal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation: Can We Improve the Evaluation of the “Gut Fitness”? 62
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis 62
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study 59
The possible role of mutated endothelial cells in myeloproliferative neoplasms 59
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION 58
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib 58
Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study 58
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION 56
Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient 55
Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50 54
Do Unexpected and Cryptic FISH Lesions Of Chromosomally Normal MDS Patients Have Any Prognostic Relevance? 51
Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor? 50
Letter in response to "Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: a Delphi Consensus" 49
Totale 10.763
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.956
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.956
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022332 0 15 11 44 13 18 19 39 22 48 22 81
2022/2023445 45 12 17 41 33 88 2 53 55 11 36 52
2023/2024808 31 21 57 52 59 154 43 45 133 27 24 162
2024/20252.506 27 60 57 246 178 181 175 123 400 238 478 343
2025/20266.009 405 549 395 734 587 455 846 308 411 595 356 368
2026/2027525 331 194 0 0 0 0 0 0 0 0 0 0
Totale 11.546